A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

✍ Scribed by A. Clamp; M. Adams; R. Atkinson; E. Boven; A.H. Calvert; A Cervantes; T. Ganesan; J. Lotz; P Vasey; P Cheverton; G.C. Jayson

• Book ID: 113959438
• Publisher: Elsevier Science
• Year: 2004
• Tongue: English
• Weight: 112 KB
• Volume: 95
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2004.06.047